The US anticoagulation therapy market is projected to reach USD 27.83 Billion by 2022 from an estimated USD 18.49 Billion in 2017, at a CAGR of 8.5%.
In 2016, C. H. Boehringer Sohn (Germany), Bristol-Myers Squibb (US), Johnson & Johnson (US), and Pfizer (US) dominated the market.
Johnson & Johnson dominated the US anticoagulation therapy market for drugs in 2016. Johnson & Johnson’s leading position in the market can be attributed to its highest selling NOAC-Xarelto. The company has a strong presence across the globe and operates through 230 wholly owned subsidiaries located in more than 60 different countries in North America, Europe, the Middle East & Africa, and Asia Pacific.
Bristol-Myers Squibb (US) and Pfizer (US) collaboratively held the second position in the US anticoagulation therapy market for drugs. The company’s patented NOAC-Eliquis-is the fastest growing NOAC in the US and is expected to hold the highest share of the NOACs market in the next five years. Eliquis is developed collaboratively by both the companies and is one of the most valuable products for both Bristol-Myers and Pfizer. Eliquis has become the most popular drug in the US in the cardiovascular segment, and the sale of this drug is expected to grow at a very high pace until 2023 when the patent on the drug is expired.
US Anticoagulation Therapy Market by Product ((Anticoagulants Drugs (NOACs, Warfarin)), PT/INR Devices (In-Office, Home Testing)), Service Type (Testing & Consulting), Type of Clinic (Hospital Associated, Independent & Pharmacy-based) - Forecast to 2022
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441